medRxiv preprint doi: https://doi.org/10.1101/2024.02.28.24303516; this version posted February 29, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

### 1 Neutrophil-to-Lymphocyte Ratio as a Prognostic Indicator in COVID-19: Evidence from

### 2 a Northern Tanzanian Cohort

- 3
- Norman J. Kyala<sup>1,2</sup>, Innocent B. Mboya<sup>3</sup>, Elichilia Shao<sup>1,2</sup>, Francis M. Sakita<sup>1,4</sup>, Kajiru G. 4
- Kilonzo<sup>1,2</sup>, Laura J Shirima<sup>3</sup>, Abid M. Sadiq<sup>1,2</sup>, Elifuraha Mkwizu<sup>1,2</sup>, Nyasatu Chamba<sup>1,2</sup>, 5
- Annette Marandu<sup>1,2</sup>, Sophia Muhali<sup>1,2</sup>, Faryal M Raza<sup>1,2</sup>, Eliasa Ndale<sup>1,2</sup>, Damasi F. Bayo<sup>1,2</sup>, 6
- Daniel P. Mujuni<sup>1,2</sup>, Furaha Lyamuya<sup>1,2</sup> 7
- 8
- 9 <sup>1</sup>Faculty of Medicine, Kilimanjaro Christian Medical University College, Moshi, Tanzania
- 10 <sup>2</sup>Department of Internal Medicine, Kilimanjaro Christian Medical Centre, Moshi, Tanzania
- 11 <sup>3</sup>Department of Epidemiology and Biostatistics, Institute of Public Health, Kilimanjaro
- Christian Medical University College, Moshi Tanzania 12
- 13 <sup>4</sup>Department of Emergency Medicine, Kilimanjaro Christian Medical Centre, Moshi, Tanzania
- 14 <sup>5</sup>Department of Translational Medicine, Lund University, 202 13 Malmö, Sweden.
- 15
- \*Corresponding author: Norman Jonas Kyala 16
- 17 E-mail: normanjonasmd@gmail.com (NJK)
- 18 <sup>¶</sup>These authors contributed equally to this work.
- 19 <sup>&</sup>These authors also contributed equally to this work.
- 20
- 21 Author emails:
- 22 IBM: innocent.mboya@med.lu.se
- 23 ES: elichilia@gmail.com
- 24 KGK: mtundumliasi@googlemail.com
- 25 AMS: abid.physician@gmail.com
- 26 FMS: francis.sakita@gmail.com
- 27 SM: muhalisophia@gmail.com
- 28 LJS: shirimalaura@gmail.com
- 29 EM: emkwizu@gmail.com
- 30 NC: nyasatuc@gmail.com
- 31 AM: annettemorio@gmail.com
- 32 FMR: faryalkmp@gmail.com
- 33 EN: eliasandale09@gmail.com
- DFB: <u>damasflavian@gmail.com</u> NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 34

- 35 DPM: danielmujuni13@gmail.com
- 36 FL: fslyamuya@gmail.com

# 37 Abstract

38 Background: COVID-19 caused a profound global impact, resulting in significant cases and 39 deaths. The progression of COVID-19 clinical manifestations is influenced by a dysregulated 40 inflammatory response. Early identification of the subclinical progression is crucial for timely 41 intervention and improved patient outcomes. While there are various biomarkers to predict 42 disease severity and outcomes, their accessibility and affordability pose challenges in resource-43 limited settings. We explored the potentiality of the neutrophil-to-lymphocyte ratio (NLR) as 44 a cost-effective inflammatory marker to predict disease severity, clinical deterioration, and 45 mortality in affected patients.

46 Methodology: A hospital-based retrospective cohort study was conducted at KCMC Hospital among COVID-19 patients followed from admission to discharge between 1st March 2020 and 47 48 31<sup>st</sup> March 2022. NLR was calculated as the absolute neutrophil count in µL divided by the 49 absolute lymphocyte count in µL. The NLR cut-off value was determined using Receiver 50 Operating Characteristic (ROC) analysis and assessed its predictive ability at admission for in-51 hospital mortality. The Chi-square test compared the proportion of NLR by patient 52 characteristics. The association of NLR with disease severity and mortality was analyzed using 53 the modified Poisson and Cox regression models, respectively.

**Results**: The study included 504 patients, with a median age of 64 years, 57.1% were males, and 68.3% had severe COVID-19. The in-hospital COVID-19 mortality rate was 37.7%. An NLR cutoff value of 6.1 or higher had a sensitivity of 92.1% (95% CI 89.2%–94.0%) and a specificity of 92.0% (95% CI 89.7%–94.4%). Additionally, 39.5% of patients with an NLR value of 6.1 or higher had increased risk of severe disease, subsequent clinical deterioration, and mortality.

60 **Conclusion and recommendation**: An NLR value of 6.1 or higher at the time of hospital 61 admission associated with severe disease, clinical deterioration, and mortality in patients with 62 COVID-19. Integration of NLR as a prognostic parameter in COVID-19 prognosis scales could 63 improve risk assessment and guide appropriate management strategies for COVID-19 patients, 64 as well as for potential future viral-related pneumonias. Further prospective studies are 65 necessary to validate these findings and evaluate the clinical utility of NLR in larger cohorts of 66 patients.

67 Keywords: Neutrophils-to-Lymphocyte ratio, Mortality, Predictors, COVID-19, Tanzania68

# 69 Introduction

70 Coronavirus disease 2019 (COVID-19), caused by the novel severe acute respiratory syndrome

- 71 coronavirus 2 (SARS-CoV-2), emerged in Wuhan, China, in late 2019 and became a global
- 72 pandemic in March 2020 (1–4). Tanzania reported its first case on March 16, 2020, with 37,091
- confirmed cases and 808 deaths as of March 4, 2023 (5).
- 74 The disease varies widely in clinical presentation as severe cases are at an increased risk of 75 mortality, hence detecting clinical deterioration early is crucial (6,7). Evidence suggests that 76 the Neutrophil-to-Lymphocyte Ratio (NLR) may serve as a marker for assessing disease 77 severity, and predicting clinical deterioration and mortality in COVID-19 patients diseases (8-78 18). NLR reflects the balance between neutrophils and lymphocytes in the blood, offering 79 insights into the immune response and inflammation. It combines changes in neutrophil and 80 lymphocyte levels, enhancing its sensitivity as an immune response marker (19–21). Clinically, 81 NLR can stratify patients, aiding in the identification of critically ill individuals (19–21).
- 82 From an immunological perspective, NLR mirrors the interplay between innate and adaptive 83 immune responses during illness and pathological stress (21). Notably, changes in the NLR 84 often occur before the occurrence of the disease's clinical manifestations, enabling early 85 detection and informing clinicians about the ongoing subclinical pathological processes 86 (Zahorec, 2001). In the context of SARS-CoV-2 infection, the mechanisms underlying the 87 response of neutrophils and lymphocytes have been postulated. Neutrophils play a crucial role 88 in activating the immune system and releasing reactive oxygen species (ROS). These ROS can 89 cause DNA damage in infected cells, leading to the release of the virus, which can then be 90 targeted by antibodies. Neutrophils can also stimulate the production of various cytokines like 91 Interleukin-8 (IL-8), Tumor necrosis factor-alpha (TNF-alpha), and Interleukin-1 beta (IL-1β), 92 as well as effector molecules including ROS, defensins, proteases, and nitric oxide (NO). 93 Conversely, systemic inflammation, particularly elevated Interleukin 6 levels in COVID-19, 94 paradoxically leads to a decrease in lymphocyte count, thereby impairing cellular immunity. 95 Both these factors contribute to an elevated NLR (8,22,23).
- Given NLR's success in predicting disease severity in various conditions, its utility among
  COVID-19 patients, particularly in resource-limited settings like Tanzania, deserves
  exploration (8–18). The study's importance lies in NLR's simplicity and cost-effectiveness
  compared to other inflammatory markers (Zahorec, 2001; Faria, Fernandes, & Silva, 2016;
  Gürağaç & Demirer, 2016; Sun et al., 2020). It can be calculated from routine blood tests,

- 101 aiding in the early identification of high-risk patients when used alongside clinical methods. If
- 102 backed with evidence, NLR can inform clinical guidelines and algorithms, enhancing COVID-
- 103 19 management and resource allocation. This research provides relevant evidence and lays the
- 104 foundation for future studies exploring NLR's broader applicability in clinical settings and
- 105 monitoring COVID-19 patients (Zahorec, 2001; Faria, Fernandes, & Silva, 2016; Gürağaç &
- 106 Demirer, 2016; Sun et al., 2020). The study evaluated NLR as a potential marker for assessing
- 107 disease severity and predicting clinical deterioration and mortality among COVID-19 patients
- 108 at Kilimanjaro Christian Medical Centre (KCMC) Hospital in Northern Tanzania.

## 109 Methods

110 Data source and population

111 This research employed a retrospective cohort study design, from March 2020 to March 2022 112 at KCMC zonal-referral Hospital with a catchment area of 15 million people located in Moshi 113 Municipality, Kilimanjaro region, northern Tanzania. The hospital has a bed capacity of over 114 640 beds. The study population consisted of 504 adult patients aged 18 years or older 115 hospitalized at KCMC with a confirmed COVID-19 diagnosis based on positive RT-PCR or antigen test results for SARS-CoV-2 conducted by the National Laboratory of Public Health 116 117 of Tanzania. We excluded pregnant women, individuals missing baseline neutrophil and/or 118 lymphocyte data, confirmed hematological malignancies, and receipt of chemotherapy, 119 immunomodulating drugs, or long-term glucocorticoids, as these conditions could potentially 120 affect neutrophil, lymphocyte, and platelet counts, leading to inaccurate NLR measurements.

Data was collected from 1<sup>st</sup> October 2022 to 31<sup>st</sup> December 2022. Data collection involved reviewing individual patient clinical files using a data extraction sheet encompassing clinical and laboratory data, including presenting symptoms, respiratory rate on admission, oxygen saturation, days from symptom onset to hospitalization, length of hospital stay, treatment outcomes, age, gender, disease severity, and documented comorbidities. Laboratory data included hemoglobin level, leukocyte count, thrombocyte count, lymphocyte count, serum creatinine, urea, aspartate transaminase (AST), and alanine aminotransferase (ALT).

128

129 Variables

130 We examined several key variables to investigate the association between NLR with patient's 131 COVID-19 outcomes. The primary outcomes were COVID-19 severity, clinical deterioration 132 during hospital admission, and COVID-19-related mortality during hospitalization. COVID-133 19 severity was categorized into four levels: mild, moderate, severe, and critical, following the 134 interim guideline of the WHO for COVID-19 (WHO, 2021). Mild cases were characterized by symptomatic patients meeting the case definition for COVID-19 without evidence of viral 135 136 pneumonia or hypoxia. Moderate cases included patients with clinical signs of pneumonia but 137 no signs of severe pneumonia, with peripheral capillary oxygen saturation (SpO2)  $\geq$  90% on 138 room air. Severe cases were defined by clinical signs of pneumonia, a respiratory rate > 30139 breaths/min, severe respiratory distress, or SpO2 < 90% on room air (WHO, 2021). Critical 140 cases were identified by criteria for Acute Respiratory Distress Syndrome (ARDS), sepsis,

septic shock, or other conditions necessitating life-sustaining therapies such as mechanical
ventilation (invasive or non-invasive) or vasopressor therapy (WHO, 2021).

143 The primary independent variables examined were the absolute neutrophil count, absolute 144 lymphocyte count recorded on admission, and the calculated NLR. NLR was calculated by 145 dividing the absolute neutrophil count in in  $\mu$ L by the absolute lymphocyte count in  $\mu$ L 146 obtained from the full blood picture of patients upon admission. NLR was analyzed both as a 147 continuous and categorical variable, with categories of normal NLR and elevated NLR. The 148 cut-off value for the categorized NLR was determined through the Receiver Operating 149 Characteristic (ROC) analysi.

# 150 Data analysis

151 The extracted data were transferred from the Excel spreadsheet to the STATA version 16 for 152 processing and analysis (24). The Chi-squared test determined the association between NLR 153 and participant characteristics. The Kruskal-Wallis test was performed to compare the medians 154 of NLR across groups of patients based on their disease severity and clinical deterioration. For 155 the assessment of clinical deterioration, the analysis focused on patients admitted with mild 156 and moderate disease, and then follow-up for clinical outcomes. The outcomes included; those 157 who did not deteriorate, those who deteriorated but survived, and those who deteriorated and 158 died.

159 To assess the diagnostic accuracy of NLR in predicting mortality among patients, ROC analysis 160 was conducted. Sensitivity and specificity values were determined, allowing for the 161 identification of a reliable threshold for predicting COVID-19 patient mortality during admission based on their NLR values. The association of elevated NLR above the cut-off value 162 163 with disease severity was examined using the modified Poisson regression model. The 164 association of NLR above the cut-off value with mortality was investigated using Cox 165 regression models. All regression models were adjusted for all statistical tests were two-sided 166 at a 5% threshold level.

167

# 168 Ethical consideration

Ethical approval was obtained from the Kilimanjaro Christian Medical University College Research and Ethics Review Committee with approval no PG/91/2022. Permission to extract hospital data was obtained from the Director of Hospital Services through the Head of the

- 172 Department of Internal Medicine at KCMC. Unique patient identification instead of hospital
- 173 medical record numbers were used to maintain confidentiality.
- 174

### Results 175

574 confirmed COVID-19 patients were admitted to KCMC Hospital between March 2020 and 176

177 March 2022, among those 504 patients were enrolled in the study after meeting the inclusion

178 criteria. The median age of the cohort was 64 years with an interquartile range (IQR) of 53-75

179 years. Among these patients, 60% were at least 61 years old, and 57.1% were males, as shown

180 in Table 1.

The median NLR values increased as the COVID-19 severity increased. Patients in the critical 181

group had the highest median NLR of 13.6 (IQR 10.3–25.9), whereas patients with mild disease 182

183 had a median NLR of 2.1 (IQR 1.7-3.4), with a p-value < 0.001 (figure 1).

184 Regarding clinical deterioration during hospital stay; in patients admitted with mild and 185 moderate COVID-19 higher NLR during admission was significantly associated with clinical 186 deterioration and progression to poor outcomes. Specifically, for patients with mild and 187 moderate COVID-19 during admission who did not deteriorate during their hospital stay, their 188 median NLR was 1.9 (IQR 1.4-2.6). For those who deteriorated to severe or critical disease 189 but were discharged alive, the median NLR was 5.6 (IQR 4.4-6.2). For patients who were 190 admitted and deteriorated to severe/critical disease and subsequently passed away, the median 191 NLR was 13.5 (IQR 6.4–24.5) (as shown in figure 2).

192 The NLR cut-off in predicting mortality due to COVID-19 determined by ROC analysis was 193 6.10 with a sensitivity of 92.1% (95% CI 89.2%-94.0%) and a specificity of 92.0% (95% CI 194 89.7%-94.4%). The AUC was 0.9207 (95% CI 0.896-0.945). The high sensitivity and 195 specificity values suggest that the NLR cut-off of 6.1 can be considered as a threshold for

196 predicting the mortality of COVID-19 patients at admission (Figure 3).

197 The distribution of NLR across background characteristics of COVID-19 patients admitted at 198 KCMC Hospital showed that out of 504 patients, 199 patients (39.5%) had a higher NLR (6.1 199 or above). Patients aged 61 years and above had the highest proportion of NLR of 6.1 or above, 200 with 139 patients (69.8%) (p-value=0.001) compared to other age groups. Although males 201 showed a slightly higher proportion of NLR of 6.1 or above 116 (40.3%) compared to females 202 83 (38.4%), the difference was not statistically significant. The second wave of COVID-19 had the highest proportion of patients with NLR of 6.1 or above 85 (44.7%) compared to other 203 204 waves of COVID-19 (p-value=0.04) (Table 1).

- 205 In terms of COVID-19 severity, a higher proportion of patients with mild COVID-19 had NLR
- below 6.1 (35 or 92.1%). It is interesting to note that among patients with severe and critical
- 207 COVID-19, 159 (46.2%) and 17 (79.9%) had NLR of 6.1 and above (Table 2).
- 208 Of all 504 patients, 140 (27.8) were admitted with mild and moderate disease. Among those
- who deteriorated and survived 8 (25.8%) had NLR of 6.1 and above compared to 14 (73.7%)
- 210 in patients who deteriorated and died (p<0.001), suggesting higher NLR to be associated with
- 211 poor progression of COVID-19 (Table 2).
- Among the patients who died during their hospital stay, a majority of 175 (91.6%) had an NLR of 6.1 or higher, p-value<0.001) (Table 2).
- 214 Individuals with a baseline NLR of 6.1 or above had a 1.43 times higher risk of developing severe and critical disease than their counterparts (RR 1.43; 95% CI 1.29-1.58, p-value= 215 216 <0.001). In addition, in the multivariable analysis, only the second and fourth waves and 217 hypertension exhibited a significant positive association with severe and critical disease (Table 218 3). Regarding COVID-19 mortality, the adjusted analysis showed that NLR had a positive 219 association with mortality. For every unit increase in NLR, the mortality risk increased by 1.03 (AHR 1.03; 95% CI 1.02–1.04, p-value < 0.001. Xx. Other factors associated with higher 220 221 mortality included age >60 years, longer duration since the first symptom, severe disease, and third COVID-19 wave (Table 4). 222

223

# 224 Discussion

225 NLR value of 6.1 was found to be the threshold value for predicting the mortality of COVID-226 19 patients during admission. Higher NLR values were observed in patients who were 61 years 227 old and above, males, those affected during the second wave of the outbreak, and those with 228 hypertension. However, only age and the waves of the outbreak showed a significant 229 association with NLR distribution. Also, higher values of NLR were found in a higher 230 proportion among patients with severe and critical COVID-19, those who were admitted with 231 mild and moderate disease later deteriorated to severe form of illness, and those who died. 232 Additionally, mortality risk increased with NLR increase. xx

233

234 The optimal cutoff value of NLR for predicting mortality in COVID-19 patients, a cutoff value 235 of 6.1 or higher, demonstrated a high sensitivity of 92.1% and specificity of 92.0%. The high 236 sensitivity and specificity suggest that NLR can serve as a valuable prognostic marker for identifying patients at higher risk of death. However, it is important to note that when 237 238 comparing our results with studies conducted in different settings, we observed variations in 239 the determined cutoff values for NLR. For instance, Prozan et al (2021), in their retrospective 240 cohort study at Tel Aviv Medical Center, identified an optimal cutoff value of 6.8 for predicting 241 poor clinical outcomes in COVID-19 patients, with a sensitivity of 67% and a specificity of 242 64%, yielding an AUC of 68.1%, (25). Similarly, Yildiz et al (2021)in their validation study in 243 Boston, USA, found an optimal cutoff value of 5.9 for predicting mortality, with a sensitivity 244 of 62% and a specificity of 64%, resulting in an AUC of 0.6653 (26). Furthermore, Citu et al 245 (2022), in an observational study conducted in Romania, identified a much higher optimal 246 cutoff value of 9.1 for predicting mortality, with a sensitivity of 70% and a specificity of 67%, 247 and an AUC of 68.9% (27). These discrepancies highlight the context-specific nature of the 248 NLR cutoff value in predicting mortality in COVID-19 patients. Several factors, such as 249 genetic variations, methodological differences, and geographical locations, could contribute to 250 the observed variations Yildiz et al (2021)(26). It is crucial to consider these factors when 251 interpreting and applying NLR as a prognostic marker in different clinical settings.

Higher NLR values were significantly associated with an increase in disease severity.
Specifically, patients with a baseline NLR of 6.1 and above were found to have a 1.43 times
higher risk of developing severe and critical disease compared to those with a baseline NLR of
less than 6.1. This association remained statistically significant even after adjusting for age,
sex, COVID-19 wave, and specific comorbidities. As the severity of COVID-19 increased, the

257 median NLR values were higher, indicating a positive correlation. These findings support the 258 potential of NLR as an indicator of disease severity in COVID-19 patients. Several studies 259 reported similar associations between NLR and disease severity in COVID-19 patients. For 260 example, Huang et al. (2020) in China found higher NLR values in severe and critical cases 261 compared to mild cases(28) while Yilmaz et al. (2020) in Turkey demonstrated an increasing 262 trend of NLR values with disease severity (29). These studies collectively support the notion 263 that NLR is associated with disease severity in COVID-19. Meta-analyses conducted by Feng 264 et al. (2020) and Ulloque-Badaracco et al. (2021) also support the strong associations between 265 elevated NLR and increased disease severity, further confirming the significance of NLR in 266 assessing disease severity (30,31). Despite variations in NLR values, the consistent trend of 267 higher NLR values corresponding to increased disease severity indicates the potential utility of NLR as an indicator for assessing disease severity in COVID-19 patients. 268

269 A significant association between baseline NLR and the subsequent deterioration of COVID-270 19 patients with mild and moderate disease to severe and critical stages or death was observed. 271 Among patients with mild and moderate disease who later deteriorated, those who were 272 discharged alive had lower median NLR values compared to those who did not survive. Similar 273 findings were reported in China where higher median NLR values at admission increased the 274 risk of clinical deterioration (32).

275

276 Furthermore, on the association between NLR and mortality in patients with COVID-19, for 277 each unit increase in NLR, the risk of in-hospital death increased by a factor of 1.03. This finding is supported by previous studies documenting higher in-hospital mortality risk for 278 279 patients with higher NLR (Ye et al., 2020; Archana, Shyamsunder and Das, 2021; Liu et al., 280 2021).

The underlying mechanisms explaining the observed outcomes can be attributed to the role of 281 282 NLR as an indicator of systemic inflammation and immune dysregulation in COVID-19. 283 Elevated NLR values reflect an imbalance between neutrophil and lymphocyte counts, 284 suggesting an exaggerated inflammatory response and compromised immune function. This 285 dysregulation can contribute to the severity of COVID-19 and increase the risk of adverse 286 outcomes, including disease severity, clinical deterioration, and mortality.

# 287 Conclusion

Our study demonstrated a significant association between the NLR and disease severity, 288 289 clinical deterioration, and mortality in COVID-19 patients. Higher NLR values were positively 290 associated with more severe disease and clinical deterioration. An NLR value of 6.1 or higher 291 predicted higher mortality risk and had high sensitivity and specificity. These findings suggest 292 the potential of NLR as a prognostic marker and highlight its potential as a reliable indicator 293 for assessing disease severity, monitoring clinical progression, and identifying patients at 294 higher risk of adverse outcomes, aiding in the effective management and treatment of COVID-295 19. Further research is warranted to explore the underlying mechanisms and validate the utility 296 of NLR in larger and more diverse patient cohorts.

297

298

- 299 Availability of data and materials
- 300 Data will be made available
- 301 Competing Interest
- 302 None of the authors has any conflict of interest in the content of this manuscript.
- 303 Acknowledgment
- 304 We acknowledge all doctors at KCMC who took part in data collection and all patients whose
- 305 information enabled the availability of data used in this study. The authors also thank the
- 306 KCMC isolation team for capturing these data in the electronic system.
- 307 Author's contributions
- 308 contributed to the design of the study. performed the statistical analysis and drafted the
- 309 manuscript. participated in the statistical analysis and drafting of the manuscript. edited the
- 310 final draft of the manuscript and approved the final manuscript.

# 311 REFERENCES

312 Baloch S, Baloch MA, Zheng T, Pei X. The Coronavirus Disease 2019 (COVID-19) 1. 313 Pandemic. Tohoku J Exp Med [Internet]. 2020 [cited 2023 Jun 21];250(4):271-8. 314 Available from: https://pubmed.ncbi.nlm.nih.gov/32321874/ 315 Cucinotta D, Vanelli M. WHO Declares COVID-19 a Pandemic. Acta Biomed 2. 316 [Internet]. 2020 [cited 2023 Jun 21];91(1):157–60. Available from: https://pubmed.ncbi.nlm.nih.gov/32191675/ 317 Al-Dadah O, Hing C. Novel Coronavirus (COVID-19): A Global Pandemic. Knee. 318 3. 319 2020 Mar 1;27(2):279. 320 Garosi VH, Tanhaie S, Chaboksavar F, Kamari T, Gheshlaghi PA, Toghroli R, et al. 4. 321 An overview of 2019 novel coronavirus COVID-19 pandemic: A review study. J Educ 322 Health Promot [Internet]. 2021 Jul 1 [cited 2023 Jun 21];10(1). Available from: 323 https://pubmed.ncbi.nlm.nih.gov/34485577/ 324 Ministry of Health Tanzania. THE UNITED REPUBLIC OF TANZANIA MINISTRY 5. 325 OF HEALTH COVID-19 WEEKLY SITUATION REPORT: NO. 77. Dodoma; 2023 326 Mar. 327 6. Wang D, Hu B, Hu C. Clinical Characteristics of 138 Hospitalized Patients With 2019 328 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020; 329 7. WHO. Clinical management Clinical management: Living guidance COVID-19. World Health Organization. 2021;(January). 330 331 8. Brüssow H. Immunology of COVID-19. Environ Microbiol. 2020 Dec 1;22(12):4895-332 905. 333 9. Mutinelli-Szymanski P, Hude I, Merle E, Lombardi Y, Seris P, Abtahi M, et al. 334 Neutrophil:lymphocyte ratio predicts short-term outcome of COVID-19 in 335 haemodialysis patients. Clin Kidney J [Internet]. 2021 Feb 3 [cited 2021 Nov 336 25]:14(1):124–31. Available from: 337 https://academic.oup.com/ckj/article/14/1/124/5998261 338 10. Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ. The 339 systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with 340 cancer. Crit Rev Oncol Hematol. 2013;88:218-30. 341 Giede-Jeppe A, Bobinger T, Gerner ST, Sembill JA, Sprügel MI, Beuscher VD, et al. 11. 342 Neutrophil-to-Lymphocyte Ratio Is an Independent Predictor for In-Hospital Mortality 343 in Spontaneous Intracerebral Hemorrhage. Cerebrovascular Diseases. 2017;44(1-344 2):26-34. 345 Azab B, Zaher M, Weiserbs KF. Usefulness of neutrophil to lymphocyte ratio in 12. 346 predicting short- and long-term mortality after non-ST-elevation myocardial infarction. 347 Am J Cardiol. 2010;106:470-6. Ha YJ, Hur J, Go DJ. Baseline peripheral blood neutrophil-to-lymphocyte ratio could 348 13. 349 predict survival in patients with adult polymyositis and dermatomyositis: A 350 retrospective observational study. PLoS One. 2018;13.

351 352 353	14.	Liu Y, Du X, Chen J, Jin Y, Peng L, Wang HHX, et al. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. Journal of Infection. 2020 Jul 1;81(1):e6–12.
354 355 356	15.	Chen G, Zhu L, Yang Y, Long Y, Li X, Wang Y. Prognostic role of neutrophil to lymphocyte ratio in ovarian cancer: A meta-analysis. Technol Cancer Res Treat. 2018 Jan 1;17.
357 358 359	16.	Nishita M, Park SY, Nishio T, Kamizaki K, Wang Z, Tamada K, et al. The relationship between hematological indices and autoimmune rheumatic diseases (ARDs), a meta- analysis. Sci Rep. 2017;7(1):1–9.
360 361	17.	Xiaohong Y, Peng L, Yuwei L. Application of neutrophil-lymphocyte ratio in the diagnosis of influenza in preschool children. Am J Health Res. 2019;7(6):100–3.
362 363 364	18.	Zhang Y, Zou P, Gao H, Yang M, Yi P, Gan J, et al. Neutrophil–lymphocyte ratio as an early new marker in AIV-H7N9-infected patients: A retrospective study. Ther Clin Risk Manag. 2019;15:911.
365 366	19.	Zahorec R. Ratio of neutrophil to lymphocyte countsrapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy. 2001;102(1):5–14.
367 368 369	20.	Gürağaç A, Demirer Z. The neutrophil-to-lymphocyte ratio in clinical practice. Canadian Urological Association Journal [Internet]. 2016 Apr 1 [cited 2022 Mar 24];10(3–4):141. Available from: /pmc/articles/PMC4839997/
370 371	21.	Faria SS, Fernandes PJ, Silva MJ. The neutrophil-to-lymphocyte ratio: a narrative review. Ecancermedicalscience. 2016;10:702.
372 373 374 375	22.	Maddani SS, Gupta N, Umakanth S, Joylin S, Saravu K. Neutrophil–Lymphocyte Ratio in Patients with COVID-19 as a Simple Tool to Predict Requirement of Admission to a Critical Care Unit. Indian J Crit Care Med [Internet]. 2021 [cited 2022 Mar 20];25(5):535. Available from: /pmc/articles/PMC8196394/
376 377	23.	Qin C, Zhou L, Hu Z. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. 2020;
378	24.	StataCorp. Stata Statistical Software: College Station, TX: StataCorp LLC; 2019.
379 380 381 382 383	25.	Prozan L, Shusterman E, Ablin J, Mitelpunkt A, Weiss-Meilik A, Adler A, et al. Prognostic value of neutrophil-to-lymphocyte ratio in COVID-19 compared with Influenza and respiratory syncytial virus infection. Scientific Reports 2021 11:1 [Internet]. 2021 Nov 2 [cited 2023 Jun 8];11(1):1–8. Available from: https://www.nature.com/articles/s41598-021-00927-x
384 385 386 387	26.	Yildiz H, Castanares-Zapatero D, Pierman G, Pothen L, De Greef J, Nana FA, et al. Validation of Neutrophil-to-Lymphocyte Ratio Cut-off Value Associated with High In-Hospital Mortality in COVID-19 Patients. Int J Gen Med [Internet]. 2021 [cited 2023 Jun 8];14:5111. Available from: /pmc/articles/PMC8420786/

388 389 390	27.	Citu C, Gorun F, Motoc A, Sas I, Gorun OM, Burlea B, et al. The Predictive Role of NLR, d-NLR, MLR, and SIRI in COVID-19 Mortality. Diagnostics [Internet]. 2022 Jan 1 [cited 2023 Jun 8];12(1). Available from: /pmc/articles/PMC8774862/
391 392 393 394 395	28.	Huang S, Liu M, Li X, Shang Z, Zhang T, Lu H. Significance of neutrophil-to- lymphocyte ratio, platelet-to-lymphocyte ratio for predicting clinical outcomes in COVID-19. medRxiv [Internet]. 2020 May 8 [cited 2022 Mar 24];2020.05.04.20090431. Available from: https://www.medrxiv.org/content/10.1101/2020.05.04.20090431v1
396 397 398 399	29.	Yılmaz E, Ak R, Doğanay F. Usefulness of the neutrophil-to-lymphocyte ratio in predicting the severity of COVID-19 patients: a retrospective cohort study. São Paulo Medical Journal [Internet]. 2022 [cited 2023 Jun 21];140(1):81. Available from: /pmc/articles/PMC9623832/
400 401 402	30.	Feng X, Li S, Sun Q, Zhu J, Chen B, Xiong M, et al. Immune-inflammatory parameters in COVID-19 cases: A systematic review and meta-analysis. Front Med. 2020;7:301.
403 404 405 406 407	31.	Ulloque-Badaracco JR, Ivan Salas-Tello W, Al-kassab-Córdova A, Alarcón-Braga EA, Benites-Zapata VA, Maguiña JL, et al. Prognostic value of neutrophil-to-lymphocyte ratio in COVID-19 patients: A systematic review and meta-analysis. Int J Clin Pract [Internet]. 2021 Nov 1 [cited 2022 Mar 24];75(11):e14596. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/jcp.14596
408	32.	Xu J bo, Xu C, Zhang R bing, Wu M, Pan C kun, Li X jie, et al. Associations of
409 410 411 412		procalcitonin, C-reaction protein and neutrophil-to-lymphocyte ratio with mortality in hospitalized COVID-19 patients in China. Scientific Reports 2020 10:1 [Internet]. 2020 Sep 14 [cited 2023 Jun 8];10(1):1–10. Available from: https://www.nature.com/articles/s41598-020-72164-7
410 411	33.	hospitalized COVID-19 patients in China. Scientific Reports 2020 10:1 [Internet]. 2020 Sep 14 [cited 2023 Jun 8];10(1):1–10. Available from:
410 411 412 413 414	33. 34.	<ul> <li>hospitalized COVID-19 patients in China. Scientific Reports 2020 10:1 [Internet].</li> <li>2020 Sep 14 [cited 2023 Jun 8];10(1):1–10. Available from: https://www.nature.com/articles/s41598-020-72164-7</li> <li>Liu L, Zheng Y, Cai L, Wu W, Tang S, Ding Y, et al. Neutrophil-to-lymphocyte ratio, a critical predictor for assessment of disease severity in patients with COVID-19. Int J</li> </ul>
410 411 412 413 414 415 416 417		<ul> <li>hospitalized COVID-19 patients in China. Scientific Reports 2020 10:1 [Internet].</li> <li>2020 Sep 14 [cited 2023 Jun 8];10(1):1–10. Available from: https://www.nature.com/articles/s41598-020-72164-7</li> <li>Liu L, Zheng Y, Cai L, Wu W, Tang S, Ding Y, et al. Neutrophil-to-lymphocyte ratio, a critical predictor for assessment of disease severity in patients with COVID-19. Int J Lab Hematol. 2021 Apr 1;43(2):329–35.</li> <li>Ye W, Chen G, Li X, Lan X, Ji C, Hou M, et al. Dynamic changes of D-dimer and neutrophil-lymphocyte count ratio as prognostic biomarkers in COVID-19. Respir Res.</li> </ul>
410 411 412 413 414 415 416 417 418 419 420 421 422 423	34.	<ul> <li>hospitalized COVID-19 patients in China. Scientific Reports 2020 10:1 [Internet].</li> <li>2020 Sep 14 [cited 2023 Jun 8];10(1):1–10. Available from:</li> <li>https://www.nature.com/articles/s41598-020-72164-7</li> <li>Liu L, Zheng Y, Cai L, Wu W, Tang S, Ding Y, et al. Neutrophil-to-lymphocyte ratio, a critical predictor for assessment of disease severity in patients with COVID-19. Int J Lab Hematol. 2021 Apr 1;43(2):329–35.</li> <li>Ye W, Chen G, Li X, Lan X, Ji C, Hou M, et al. Dynamic changes of D-dimer and neutrophil-lymphocyte count ratio as prognostic biomarkers in COVID-19. Respir Res. 2020 Jul 3;21(1).</li> <li>Archana B, Shyamsunder S, Das R. Validity of Markers and Indexes of Systemic Inflammation in Predicting Mortality in COVID-19 infection: A Hospital based Cross Sectional Study. Journal of Cardiac and Pulmonary Rehabilitation [Internet]. 2021 Sep 13 [cited 2022 Jul 16];5(4):1–6. Available from: https://www.omicsonline.org/openaccess/validity-of-markers-and-indexes-of-systemic-inflammation-in-predicting-</li> </ul>

### 428 Table 1: Distribution of NLR across background characteristics of COVID-19 patients

		NLR		
Characteristic	Total	NLR< 6.1	$NLR \ge 6.1$	*P- value
		n (%)	n (%)	
Age (years)				
Median (IQR)	64(53-75)	XX		
18 - 30	19 (3.6)	11 (61.1)	8 (38.9)	0.001
31 - 60	183 (36.4)	131 (71.6)	52 (28.4)	
61 and above	302 (60)	163 (54)	139 (46)	
Sex				
Male	288 (57.1)	172 (59.7)	116 (40.3)	0.674
Female	216 (42.9)	133 (61.6)	83 (38.4)	
COVID-19 Waves				
Wave 1	111 (22.0)	80 (72.1)	31 (27.9)	0.036
Wave 2	190 (37.7	105 (55.3)	85 (44.7)	
Wave 3	119 (23.6)	70 (58.8)	49 (41.2)	
Wave 4	84 (16.7)	50 (59.5)	34 (40.5)	
Comorbidities (Yes)			<b>``</b>	
Diabetes mellitus	160 (31.8)	93 (58.1)	67 (41.9)	0.454
Hypertension	260 (51.6)	154 (60.5)	106 (40.5)	0.542
HIV/AIDS	13 (2.6)	9 (69.2)	4 (30.8)	0.232
Chronic kidney disease	34 (6.8)	19 (55.9)	15 (39.1)	0.576
Other comorbidities	14 (2.8)	9 (64.3)	5 (36.7)	0.563

429 admitted at KCMC Hospital between March 2020 to March 2022 (N=504)

430 Abbreviations: HIV/AIDS, Human Immunodeficiency Virus / Acquired Immunodeficiency Syndrome. NLR,

431 Neutrophil to Lymphocyte Ratio. \*P-value from the Chi-squared distribution.

- 432
- 433

434 Table 2: Distribution of NLR across clinical outcomes of patients admitted with COVID-19 at

435 KCMC hospital between March 2020 to March 2022. (N = 504)

Clinical outcome	Total	NLR < 6.1	$NLR \ge 6.1$	*P-value
		n = 305	n = 199	
COVID-19 Severity				
Mild	38 (7.5)	35 (92.1)	3 (7.9)	< 0.001
Moderate	102 (20.2)	82 (80.4)	20 (19.6)	
Severe	344 (68.3)	185 (53.8)	159 (46.2)	
Critical	20 (4.0)	3 (15)	17 (85)	
Clinical deterioration (n=xxx)				
No	90 (64.3)	89 (98.9)	1 (1.1)	< 0.001
Yes, and discharged alive	31 (22.1)	23 (74.2)	8 (25.8)	
Yes, and dead	19 (13.6)	5 (26.3)	14 (73.7)	
Mortality from COVID-19				
Dead	190 (37.7)	16 (8.4)	174 (91.6)	
Alive	314 (62.3)	289 (92.0)	25 (8.0)	< 0.001

436 Abbreviations: NLR, Neutrophil to Lymphocyte Ratio. \*P-value from the Chi-squared distribution.

- Table 4: Factors associated with Severe Disease in Patients Admitted with COVID-19 at

442	KCMC Hospital: March 2020 to March 2022 (N = 504)						
	Variable	CRR (95% CI)	P-Value	ARR*			
	NUL D						

Variable	CRR (95% CI)	P-Value	ARR* (95% CI)	P-value
NLR				
Normal NLR	1		1	
Elevated NLR	1.43 (1.29 – 1.58)	< 0.001	1.39 (1.26 – 1.55)	< 0.001
Age Groups (Years)				
18 - 30	1		1	
31 - 60	1.11 (0.76 – 1.62)	0.596	1.07 (0.75 – 1.53)	0.713
61 and above	1.23 (0.84 - 1.80)	0.269	1.10 (0.78 - 1.56)	0.59
Sex				
Male	0.98 (0.89 - 1.10)	0.841	1.02 (0.92 -1.14)	0.687
Female	1		1	
Comorbidity				
Hypertension	1.12 (1.00 – 1.25)	0.044	1.12 (1-1.25)	0.054
Diabetes Mellitus	1.04(0.93 - 1.17)	0.453	1 (0.89 – 1.12)	0.944
HIV/AIDS	0.68 (0.21 - 2.18)	0.518	0.98(0.87 - 1.1)	0.747
Chronic Kidney Disease	0.88 (0.69 - 1.15)	0.366	0.85 (0.66 -1.1)	0.228
Other comorbidities	0.69(0.23 - 2.21)	0.527	0.98(0.89 - 1.12)	0.821
COVID-19 Waves				
Wave 1	1		1	
Wave 2	1.32 (1.11 – 1.56)	0.002	1.24 (1.04 – 1.47)	0.015
Wave 3	1.19 (0.98 - 1.44)	0.081	1.13 (0.93 – 1.36)	0.216
Wave 4	1.30 (1.07 – 1.58)	0.007	1.24 (1.02 – 1.50)	0.029

Abbreviations: CRR, Crude Relative Risk. ARR, Adjusted Relative Risk. CI, Confidence Intervals. NLR, Neutrophil to Lymphocyte Ratio. HIV/AIDS, Human Immunodeficiency Virus / Acquired Immunodeficiency Syndrome. Adjusted risk ratios derived from the Modified Poison Regression Model (the generalized linear regression model with the Poisson family and log link function). \* Model adjusted for age groups, sex, co-morbidities, and COVID-19 waves.

- Table 5: NLR and other factors associated with in-hospital death AMONG patients admitted

451	with COVID-19 at KCMC hospital ( $N = 504$ )	)
-----	--	---

Variable	CHR (95%CI)	P-value	AHR (95%CI)	P-value
NLR	1.03 (1.027-1.036)	< 0.001	1.03 (1.021-1.038)	< 0.001
Age				
18-30	0.83 (0.385-1.777)	0.63	1.68 (0.835-3.360)	0.15
31-60	0.46 (0.331-0.648)	< 0.001	0.53 (0.365-0.761)	< 0.001
>60	1.00		1	
Sex				
Female	1		1	
Male	1.12 (0.838-1.501)	0.44	1.08 (0.790-1.469)	0.64

Duration since first symptoms (days)				
<7	1		1	
8-14	0.51 (0.349-0.749)	0.001	0.51 (0.341-0.758)	0.001
15-21	0.39 (0.197-0.765)	0.006	0.36 (0.188-0.699)	0.002
≥22	0.21 (0.096-0.456)	< 0.001	0.21 (0.093-0.339)	< 0.001
Disease severity	· · · · ·		· · · · · ·	
Mild and moderate	1		1	
Severe and critical	3.52 (2.162-5.715)	< 0.001	2.74 (1.694-4.437)	< 0.001
COVID-19 Waves				
Wave 1	1		1	
Wave 2	1.84 (1.175-2.880)	0.01	1.10 (0.662-1.845)	0.70
Wave 3	2.29 (1428-3.666)	0.001	0.94 (0.547-1.611)	0.82
Wave 4	2.57 (1.553-4.252)	< 0.001	1.87 (1.178-2.979)	0.01
Comorbidity				
Diabetes (yes)	1.14 (0.848-1.546)	0.38		
Asthma/chronic lung disease	1.03 (0.508-2.099)	0.93		
(yes)				
HIV (yes)	0.68 (0.251-1.828)	0.44		
Other comorbidities (yes)	0.69 (0.253–1.924)	0.53		
Hypertension (yes)	1.24 (0.930-1.660)	0.14	1.10 (0.800-1.500)	0.57

452 453 454 455 Abbreviations: CHR, Crude Hazard Ratio. AHR, Adjusted Hazard Ratio. CI, Confidence Intervals. NLR, Adjusted hazard ratios derived from the Modified Poison Regression Model (the generalized linear regression model with the Poisson family and log link function). \* Model adjusted for age groups, sex, co-morbidities, and COVID-19 waves.

456




Figure 1: The distribution of NLR across categories of disease severity in COVID-19 patients admitted at KCMC Hospital (N = 504). \* P-value from Kruskal-Wallis test Figure




Figure 2: The distribution of NLR among patients with mild and moderate disease in relation to deterioration to severe disease or death. (N = 140). \* P-Value from Kruskal-Wallis test Figure




Figure 3: Diagnostic accuracy of NLR on predicting mortality among confirmed COVID-19 Patients at KCMC Hospital: March 2020 to March 2022. (N= 504).

# Figure